Francisco A Moreno1, Robert P Erickson2, Holly A Garriock3, Joel Gelernter4, Jim Mintz5, Jennifer Oas-Terpstra6, Marilyn A Davies7, Pedro L Delgado8. 1. Department of Psychiatry, College of Medicine, The University of Arizona Health Sciences Center, USA. 2. Department of Pediatrics, College of Medicine, The University of Arizona Health Sciences Center, USA. 3. Division of Translational Research (DTR), National Institute of Mental Health, USA. 4. Department of Psychiatry, Yale University School of Medicine, VA Connecticut Health Care Center, USA. 5. Department of Psychiatry, University of Texas Health Sciences Center San Antonio, USA. 6. Department of Physiology, College of Medicine, The University of Arizona Health Sciences Center, USA. 7. Health and Community Systems, University of Pittsburgh School of Nursing, USA. 8. Department of Psychiatry, University of Arkansas for Medical Sciences, USA.
Abstract
PURPOSE: The brief and reversible mood response to acute tryptophan (TRP) depletion (ATD) is being studied as a trait marker in subjects considered at risk for major depression (MD). PROCEDURES: ATD was administered to 64 subjects (54 European-Americans, and10 from other races) with personal and family history of MD. They were in remission and had been medication-free for at least three months. Subjects received an active and sham condition in a random assignment, double-blind crossover design. They were genotyped for serotonin-related candidate genes, and mood response was quantified with the Hamilton Depression Rating Scale (HDRS). Data were analyzed using Poisson regression with repeated measures and latent trajectory models. RESULTS: Compared to the sham control, active ATD caused modest depressive changes showing significant main effects of test condition (χ2=5.14, df=1, p=0.023) and time (χ2=12.22, df=3, p=0.007), but no significant interaction of time and test condition. Latent trajectory analysis revealed two groups, identified as depletion responders and non-responders. Those with the HTR2A rs6313 CC genotype had significantly higher HDRS scores during ATD (χ2=11.72, df=1, p=.0006). CONCLUSIONS AND MESSAGE: ATD may help the identification of biological subtypes of MD. These data are consistent with imaging reports implicating 5-HT2A receptor function in ATD phenotypes.
RCT Entities:
PURPOSE: The brief and reversible mood response to acute tryptophan (TRP) depletion (ATD) is being studied as a trait marker in subjects considered at risk for major depression (MD). PROCEDURES: ATD was administered to 64 subjects (54 European-Americans, and10 from other races) with personal and family history of MD. They were in remission and had been medication-free for at least three months. Subjects received an active and sham condition in a random assignment, double-blind crossover design. They were genotyped for serotonin-related candidate genes, and mood response was quantified with the Hamilton Depression Rating Scale (HDRS). Data were analyzed using Poisson regression with repeated measures and latent trajectory models. RESULTS: Compared to the sham control, active ATD caused modest depressive changes showing significant main effects of test condition (χ2=5.14, df=1, p=0.023) and time (χ2=12.22, df=3, p=0.007), but no significant interaction of time and test condition. Latent trajectory analysis revealed two groups, identified as depletion responders and non-responders. Those with the HTR2Ars6313 CC genotype had significantly higher HDRS scores during ATD (χ2=11.72, df=1, p=.0006). CONCLUSIONS AND MESSAGE: ATD may help the identification of biological subtypes of MD. These data are consistent with imaging reports implicating 5-HT2A receptor function in ATD phenotypes.
Authors: P Quintin; C Benkelfat; J M Launay; I Arnulf; A Pointereau-Bellenger; S Barbault; J C Alvarez; O Varoquaux; F Perez-Diaz; R Jouvent; M Leboyer Journal: Biol Psychiatry Date: 2001-08-01 Impact factor: 13.382
Authors: J S Rubinsztein; R D Rogers; W J Riedel; M A Mehta; T W Robbins; B J Sahakian Journal: Psychopharmacology (Berl) Date: 2001-03 Impact factor: 4.530
Authors: Xianzhang Hu; Gabor Oroszi; Jeffrey Chun; Tom L Smith; David Goldman; Marc A Schuckit Journal: Alcohol Clin Exp Res Date: 2005-01 Impact factor: 3.455
Authors: Jonathan P Roiser; Jamey Levy; Stephen J Fromm; David Goldman; Colin A Hodgkinson; Gregor Hasler; Barbara J Sahakian; Wayne C Drevets Journal: J Psychopharmacol Date: 2012-04-10 Impact factor: 4.153
Authors: Allison C Nugent; Alexander Neumeister; David Goldman; Peter Herscovitch; Dennis S Charney; Wayne C Drevets Journal: Neuroimage Date: 2008-07-30 Impact factor: 6.556
Authors: F Haghighi; H Bach-Mizrachi; Y Y Huang; V Arango; S Shi; A J Dwork; G Rosoklija; H T Sheng; I Morozova; J Ju; J J Russo; J J Mann Journal: Mol Psychiatry Date: 2008-01-08 Impact factor: 15.992
Authors: Joanna Moncrieff; Ruth E Cooper; Tom Stockmann; Simone Amendola; Michael P Hengartner; Mark A Horowitz Journal: Mol Psychiatry Date: 2022-07-20 Impact factor: 13.437
Authors: Simone M E Schopman; Renske C Bosman; Anna D T Muntingh; Anton J L M van Balkom; Neeltje M Batelaan Journal: Transl Psychiatry Date: 2021-02-11 Impact factor: 6.222
Authors: Maria Becker; Karin Abaev; Elena Shmerkin; Liza Weinstein-Fudim; Albert Pinhasov; Asher Ornoy Journal: Int J Mol Sci Date: 2022-10-07 Impact factor: 6.208